Article: Immunogenicity and safety of heterologous booster with protein-based COVID-19 vaccine (NVX-CoV2373) in healthy adults: A comparative analysis with mRNA vaccines.
Journal of the Formosan Medical Association = Taiwan yi zhi
2023 Volume 123, Issue 3, Page(s) 340–346
Abstract: Background: Information on the protein-based severe acute respiratory syndrome (SARS-CoV-2) vaccine-NVX-CoV2373 (Novavax), as a heterologous booster remains limited. We investigated the immunogenicity and adverse events of NVX-CoV2373 as a second ... ...
| Abstract | Background: Information on the protein-based severe acute respiratory syndrome (SARS-CoV-2) vaccine-NVX-CoV2373 (Novavax), as a heterologous booster remains limited. We investigated the immunogenicity and adverse events of NVX-CoV2373 as a second booster and compared them with those of mRNA vaccines in healthy adults. Methods: Healthcare workers who had received an mRNA vaccine (mRNA-1273 or BNT-162b2) as the first booster (third dose) 12 weeks prior were recruited. Participants voluntarily received either NVX-CoV2373 or an mRNA vaccine as a second booster. Participants with a history of SARS-CoV-2 infection were excluded. The primary outcomes included serum anti-SARS-CoV-2 spike protein (SP) and neutralizing antibody titers against B.1.1.7 (Alpha), B.1.1.529 (Omicron) BA2, and BA5 variants on the 28th day after the boost. Secondary outcomes included new SARS-CoV-2 infections and adverse events reported during the study period. Results: A total of 160 participants were enrolled in this study. Compared with the mRNA vaccination group (n = 59), the NVX-CoV2373 vaccination group (n = 101) had significantly lower anti-SARS-CoV-2 SP antibody titers and neutralizing antibody titers against all variants tested after the boost. During the study period, higher rates of new SARS-CoV-2 infections and a lower incidence of adverse events were observed in the NVX-CoV2373 vaccination group. No significant differences in cellular immune responses were observed between the two groups. Conclusion: Compared to a homologous mRNA booster vaccination, heterologous boosters with NVX-CoV2373 showed lower antibody responses, a higher incidence of new SARS-CoV-2 infections, and fewer adverse events. |
|---|---|
| MeSH term(s) | Adult ; Humans ; COVID-19 Vaccines/adverse effects ; mRNA Vaccines ; SARS-CoV-2 ; COVID-19/prevention & control ; RNA, Messenger ; Antibodies, Neutralizing ; Antibodies, Viral |
| Chemical Substances | NVX-CoV2373 adjuvated lipid nanoparticle (2SCD8Q63PF) ; COVID-19 Vaccines ; mRNA Vaccines ; RNA, Messenger ; Antibodies, Neutralizing ; Antibodies, Viral |
| Language | English |
| Publishing date | 2023-11-22 |
| Publishing country | Singapore |
| Document type | Journal Article |
| ZDB-ID | 2096659-3 |
| ISSN | 1876-0821 ; 0929-6646 |
| ISSN (online) | 1876-0821 |
| ISSN | 0929-6646 |
| DOI | 10.1016/j.jfma.2023.10.012 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 1041: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.